Flamel Technologies Announces Multi-year supply agreement with GlaxoSmithKline …
LYON, France – (BUSINESS WIRE) – Flamel Technologies (Nasdaq: FLML) announced today that it has completed a multi-year supply agreement with GlaxoSmithKline (NYSE: GSK) for the production of Coreg CR microparticles. Flamel Technologies is the & amp; nbsp; …
Read more at Business Wire (press release) code

Recipharm adds French plant and drug delivery tech in strategic deal with Flamel
… all ongoing Flamel business currently being carried out at the plant, including the manufacture of Flamel's pipeline and micropump-based microparticles for Coreg CR (carvedilol phosphate), a congestive heart failure marketed by GlaxoSmithKline in …
Read more on OutSourcing-Pharma.com